Integration of vitamin A supplementation with the expanded program on immunization does not affect seroconversion to oral poliovirus vaccine in infants.
Childhood immunization programs may provide infrastructure for delivering vitamin A supplements to infants in developing countries. The effect of giving vitamin A, an immune enhancer, on antibody responses to trivalent oral poliovirus vaccine (TOPV) is unknown. A randomized, double-blind, placebo-controlled clinical trial was conducted to determine the effect of giving vitamin A simultaneously with TOPV on antibody responses to poliovirus. Infants (n = 467) received oral vitamin A, 15 mg retinol equivalent (RE), 7.5 mg RE or placebo with TOPV at 6, 10 and 14 wk of age. Antibody responses to poliovirus types 1, 2 and 3 were measured by a microvirus neutralization assay at enrollment and at 9 mo of age. Seroconversion rates to poliovirus types 1, 2 and 3 ranged from 98 to 100% in the three treatment groups, and there were no differences in mean antibody titers to poliovirus types 1, 2 and 3 among treatment groups. This study demonstrates that oral vitamin A does not affect antibody responses to poliovirus vaccine when integrated with the Expanded Program on Immunization.
Semba
R D
RD
Department of Ophthalmology, School of Medicine, Johns Hopkins University, Baltimore, MD 21287, USA.
Muhilal
Mohgaddam
N E
NE
Munasir
Z
Z
Akib
A
A
Permaesih
D
D
Muherdiyantiningsih
Osterhaus
A
A
D000328:Adult; D000914:Antibodies, Viral / Q000032:analysis*; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007114:Immunization; D007223:Infant; D008297:Male; D011055:Poliovirus Vaccine, Oral / Q000276:immunology*; D014801:Vitamin A / Q000008:administration & dosage* / Q000494:pharmacology
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral; D014801:Vitamin A